📊 STOK Key Takeaways
Is Stoke Therapeutics, Inc. (STOK) a Good Investment?
Stoke Therapeutics demonstrates compelling commercial traction with 404% revenue growth paired with positive free cash flow of $44.9M and zero debt, indicating successful product commercialization with clear profitability inflection approaching. The pristine balance sheet ($352.5M equity, $84.2M cash) and improving net loss trajectory despite operating losses suggest the company has substantial financial runway and is transitioning from growth phase to sustainable profitability.
Why Buy Stoke Therapeutics, Inc. Stock? STOK Key Strengths
- Exceptional 404% YoY revenue growth demonstrating successful product commercialization and market adoption
- Positive free cash flow of $44.9M with 24.4% FCF margin despite current operating losses, indicating underlying business health
- Fortress balance sheet with $352.5M stockholders' equity, zero long-term debt, and 5.28x current ratio providing substantial financial flexibility
- Improving profitability metrics with net loss stabilizing as revenue scales 400%+ YoY
STOK Stock Risks: Stoke Therapeutics, Inc. Investment Risks
- Company remains operationally unprofitable with -$20.6M operating income and -11.2% operating margin despite revenue scale
- Pharmaceutical sector inherent risks including regulatory approval, clinical outcome variability, and competitive pressures
- High insider trading activity (21 Form 4 filings in 90 days) requires monitoring for potential sentiment shifts
- Profitability inflection not yet demonstrated; continued losses could pressure cash burn if revenue growth decelerates
Key Metrics to Watch
- Operating margin progression toward breakeven and profitability as revenue scales
- Free cash flow sustainability and whether positive FCF persists through profitability transition
- Revenue growth rate trajectory and deceleration pattern to assess market saturation
- Operating income improvement and timeline to positive EBITDA as cost structure optimizes
Stoke Therapeutics, Inc. (STOK) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 24.4% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 5.28x current ratio provides a solid financial cushion.
STOK Profit Margin, ROE & Profitability Analysis
STOK vs Healthcare Sector: How Stoke Therapeutics, Inc. Compares
How Stoke Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Stoke Therapeutics, Inc. Stock Overvalued? STOK Valuation Analysis 2026
Based on fundamental analysis, Stoke Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Stoke Therapeutics, Inc. Balance Sheet: STOK Debt, Cash & Liquidity
STOK Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Stoke Therapeutics, Inc.'s revenue has grown significantly by 1,387% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.65 indicates the company is currently unprofitable.
STOK Revenue Growth, EPS Growth & YoY Performance
STOK Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $4.9M | -$23.5M | $-0.47 |
| Q2 2025 | $4.8M | -$23.5M | $-0.40 |
| Q1 2025 | $4.2M | -$26.4M | $-0.57 |
| Q3 2024 | $3.3M | -$22.5M | $-0.47 |
| Q2 2024 | -$2.5M | -$22.5M | $-0.46 |
| Q1 2024 | $4.2M | -$22.5M | $-0.53 |
| Q3 2023 | $2.9M | -$22.5M | $-0.55 |
| Q2 2023 | -$2.5M | -$22.5M | $-0.63 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Stoke Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
STOK SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Stoke Therapeutics, Inc. (CIK: 0001623526)
📋 Recent SEC Filings
❓ Frequently Asked Questions about STOK
What is the AI rating for STOK?
Stoke Therapeutics, Inc. (STOK) has an AI rating of BUY with 73% confidence, based on fundamental analysis of SEC EDGAR filings.
What are STOK's key strengths?
Claude: Exceptional 404% YoY revenue growth demonstrating successful product commercialization and market adoption. Positive free cash flow of $44.9M with 24.4% FCF margin despite current operating losses, indicating underlying business health.
What are the risks of investing in STOK?
Claude: Company remains operationally unprofitable with -$20.6M operating income and -11.2% operating margin despite revenue scale. Pharmaceutical sector inherent risks including regulatory approval, clinical outcome variability, and competitive pressures.
What is STOK's revenue and growth?
Stoke Therapeutics, Inc. reported revenue of $184.4M.
Does STOK pay dividends?
Stoke Therapeutics, Inc. does not currently pay dividends.
Where can I find STOK SEC filings?
Official SEC filings for Stoke Therapeutics, Inc. (CIK: 0001623526) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is STOK's EPS?
Stoke Therapeutics, Inc. has a diluted EPS of $-0.12.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is STOK a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Stoke Therapeutics, Inc. has a BUY rating with 73% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is STOK stock overvalued or undervalued?
Valuation metrics for STOK: ROE of -2.0% (sector avg: 15%), net margin of -3.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy STOK stock in 2026?
Our dual AI analysis gives Stoke Therapeutics, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is STOK's free cash flow?
Stoke Therapeutics, Inc.'s operating cash flow is $45.6M, with capital expenditures of $670.0K. FCF margin is 24.4%.
How does STOK compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -3.7% (avg: 12%), ROE -2.0% (avg: 15%), current ratio 5.28 (avg: 2).